A Marco Alings

beroep: onderzoeker

Series

There is nothing here

Create a new serie

Werken

There is nothing here

Create a new work

Artikels 37

Date

Titel

Auteurs

2020-09-01

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Johan Lindbäck, Agneta Siegbahn, Lars Wallentin, Jonas Oldgren, Christopher B. Granger, Renato Delascio Lopes, John H. Alexander, Michael D. Ezekowitz, Raffaele De Caterina, A Marco Alings, John W. Eikelboom, Elaine Hylek, Ziad Hijazi, Claes Held
2019-04-01

Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study

Michiel Rienstra, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, Hans L Hillege, Marcelle D Smit, Robert G. Tieleman, Jan G. P. Tijssen, A Marco Alings, Adelita Vijaynti Ranchor, Bastiaan Geelhoed, Anne H Hobbelt, Martin E W Hemels, Johan Brügemann, Bob Weijs, Raymond Tukkie
2019-03-18

Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation

Nikki A H A Pluymaekers, Elton Dudink, Joan G Meeder, Isabelle C Van Gelder, Harry J. G. M. Crijns, Michiel Rienstra, Jan G. P. Tijssen, A Marco Alings, Justin G L M Luermans
2018-02-01

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Tria

Cetin Erol, Christopher B. Granger, Claes Held, Johan Lindbäck, Witold RużyłłO, Renato Delascio Lopes, John H. Alexander, A Marco Alings, Tymon Pol, Ziad Hijazi, Sigrun Halvorsen, Shinya Goto, Michael Hanna
2018-08-01

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial

Michiel Rienstra, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, Hans L Hillege, Marcelle D Smit, Robert G. Tieleman, Jan G. P. Tijssen, A Marco Alings, RACE II Investigators, Bastiaan Geelhoed, Anne H Hobbelt, Johan Brügemann, Raymond Tukkie
2018-09-12

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation

Bernard J Gersh, Agneta Siegbahn, Lars Wallentin, Christopher B. Granger, Renato Delascio Lopes, John H. Alexander, Raffaele De Caterina, A Marco Alings, Sigrun Halvorsen, Elaine Hylek, Christina Christersson, Byung-Hee Oh, Michael Hanna
2017-11-10

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Aldo P. Maggioni, Shrikant I Bangdiwala, John W. Eikelboom, Salim Yusuf, Kelley Branch, Stefan Störk, Patricio Lopez-Jaramillo, Alvaro Avezum, Jackie Bosch, Martin O'Donnell, A Marco Alings, Sonia Anand, Deepak L. Bhatt, Patrick J Commerford, K A Fox, Katalin Keltai, Victor Aboyans, COMPASS Investigators, Nana-Goar V Pogosova, Darryl P Leong, T Vanassche
2017-06-08

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Aldo P. Maggioni, Christian Torp-Pedersen, John W. Eikelboom, Philippe Gabriel Steg, Paul Moayyedi, Salim Yusuf, Petr Widimský, Alvaro Avezum, Tomasz J Guzik, Camilo Felix, Mukul Sharma, Stefan Störk, Fernando Lanas, Patricio Lopez-Jaramillo, Jong-Won Ha, Jackie Bosch, Martin O'Donnell, Kaj Metsärinne, Eva Lonn, Katalin Keltai, Masatsugu Hori, Khalid Yusoff, Deepak L. Bhatt, Kelley Branch, Nancy Cook Bruns, Sonia Anand, John Varigos, K A Fox, Frank Misselwitz, Edmond Chen, A Marco Alings, Leopoldo S. Piegas, Jeffrey L Probstfield, Matyas Keltai, Gilles R Dagenais, Nana-Goar V Pogosova, Patrick J Commerford, Peter Verhamme, Andrew Tonkin, Darryl P Leong, Andre Lamy, Victor Aboyans, Vivian Lanius
2017-04-24

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.

Christopher B. Granger, Giuseppe Boriani, Renato Delascio Lopes, A. John Camm, Stefan H Hohnloser, A Marco Alings
2017-08-27

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Aldo P. Maggioni, Christian Torp-Pedersen, John W. Eikelboom, Salim Yusuf, Petr Widimský, Alvaro Avezum, Camilo Felix, Olga Shestakovska, Stefan Störk, Patricio Lopez-Jaramillo, Jackie Bosch, Martin O'Donnell, Fernando Lanas, Kaj Metsärinne, Eva Lonn, Masatsugu Hori, Khalid Yusoff, Deepak L. Bhatt, Kelley Branch, Nancy Cook Bruns, Sonia Anand, K A Fox, Frank Misselwitz, Edmond Chen, A Marco Alings, Leopoldo S. Piegas, Jeffrey L Probstfield, Matyas Keltai, Gilles R Dagenais, Nana-Goar V Pogosova, Patrick J Commerford, Peter Verhamme, Andrew Tonkin, Darryl P Leong, COMPASS Investigators, Philippe Gabriel Steg
2016-12-22

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Wiek H van Gilst, Christopher B. Granger, Lars Wallentin, Laine Thomas, Renato Delascio Lopes, John H. Alexander, Raffaele De Caterina, A Marco Alings, Elaine Hylek, Philippe Gabriel Steg, Daniel Wojdyla, Matyas Keltai, Michael Hanna
2016-11-07

Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial

Christopher B. Granger, Lars Wallentin, Laine Thomas, Renato Delascio Lopes, John H. Alexander, A Marco Alings, Daniel Wojdyla, Sana M Al-Khatib, J D Horowitz, Michael Hanna
2014-06-09

Digoxin in patients with permanent atrial fibrillation: data from the RACE II study

Michiel Rienstra, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, B A Mulder, Hans L Hillege, Jan G. P. Tijssen, A Marco Alings, Maarten P van den Berg, RACE II Investigators
2014-12-12

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

Christopher B. Granger, Lars Wallentin, Claes Held, Laine Thomas, Witold RużyłłO, Renato Delascio Lopes, John H. Alexander, Mårten Rosenqvist, Daniel Wojdyla, Freek W A Verheugt, Elaine Hylek, Jack Ansell, Husayn al-Khalidi, A Marco Alings, Shinya Goto, Michael Hanna
2014-09-03

Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.

Olga Shestakovska, John W. Eikelboom, Alvaro Avezum, Stefan H Hohnloser, A Marco Alings, Mandy N Lauw, T Vanassche
2014-06-17

Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study.

Michiel Rienstra, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, Hans L Hillege, Jan G. P. Tijssen, A Marco Alings, Maarten P van den Berg, Rob A Vermond, RACE II Investigators
2014-01-01

Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".

Claes Held, Philippe Gabriel Steg, Cetin Erol, Christopher B. Granger, Veli-Pekka Harjola, Lars Wallentin, Laine Thomas, Witold RużyłłO, Renato Delascio Lopes, John H. Alexander, Raffaele De Caterina, Mårten Rosenqvist, John McMurray, Philip Aylward, Sana M Al-Khatib, Steen E Husted, Matyas Keltai, Anne Hellkamp, Elaine Hylek, Jack Ansell, Patrick J Commerford, Fernando Lanas, John Amerena, A Marco Alings, Jozef Bartunek, J D Horowitz, Byung-Hee Oh, Michael Hanna
2013-06-12

Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study

Michiel Rienstra, Hessel F Groenveld, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, B A Mulder, Hans L Hillege, Jan G. P. Tijssen, A Marco Alings, Maarten P van den Berg, RACE II Investigators
2013-10-20

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

Philippe Gabriel Steg, Christopher B. Granger, Lars Wallentin, Dan Atar, Laine Thomas, Renato Delascio Lopes, John H. Alexander, John McMurray, A Marco Alings, Steen E Husted, Philip Aylward, Daniel Wojdyla, Prem Pais, Freek W A Verheugt, Shinya Goto, Michael Hanna
2013-04-17

Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial

Justin A. Ezekowitz, Christopher B. Granger, Lars Wallentin, Laine Thomas, Bernard J Gersh, Renato Delascio Lopes, John H. Alexander, A Marco Alings, Sana M Al-Khatib, Gregory Flaker, Michael Hanna
2013-05-02

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.

Claes Held, Philippe Gabriel Steg, Elaine Hylek, Cetin Erol, Christopher B. Granger, Veli-Pekka Harjola, Lars Wallentin, Laine Thomas, Witold RużyłłO, Renato Delascio Lopes, John H. Alexander, Raffaele De Caterina, Mårten Rosenqvist, John McMurray, Philip Aylward, Sana M Al-Khatib, Steen E Husted, Matyas Keltai, Anne Hellkamp, Jack Ansell, Patrick J Commerford, Fernando Lanas, John Amerena, A Marco Alings, Jozef Bartunek, J D Horowitz, Byung-Hee Oh, Michael Hanna
2013-06-14

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Andrzej Budaj, Jorge Ferreira, David A. Halon, Leopoldo S. Piegas, Mario Talajic, R Tan, Lars Wallentin, Jonas Oldgren, Hein Heidbuchel, Alvaro Avezum, Michael D. Ezekowitz, Jean-Yves Le Heuzey, Stefan H Hohnloser, John W. Eikelboom, Muredach P Reilly, A Marco Alings, Ellison Themeles, Harald Darius, Maria Grazia Franzosi, Prem Pais, Gabriel Kamenský, John Amerena, Matyas Keltai, Yusuf M Salim, Chu-Pak Lau, Sung Soon Kim, Jyh-Hong Chen, Supachai Tanomsup, Lauri Toivonen
2012-05-08

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

Christopher B. Granger, Lars Wallentin, Hans-Christoph Diener, Renato Delascio Lopes, John H. Alexander, Mårten Rosenqvist, A Marco Alings, Daniel Wojdyla, ARISTOTLE Committees and Investigators, J Donald Easton, Shinya Goto, Puneet Mohan, Michael Hanna
2012-11-28

Anxiety and risk of ventricular arrhythmias or mortality in patients with an implantable cardioverter defibrillator.

Susanne S. Pedersen, Luc Jordaens, Johan Denollet, Dominic A Theuns, A Marco Alings, Pepijn H van der Voort, Krista C van den Broek, Mirela Habibović
2012-01-24

Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Tria

Lars Wallentin, John W. Eikelboom, Hans-Christoph Diener, Salim Yusuf, Jonas Oldgren, Stefan H Hohnloser, Muredach P Reilly, A Marco Alings, Jeanne Varrone, Maria Grazia Franzosi, Sean Yang, Mike Ezekowitz, Scott Kaatz
2011-12-15

Dronedarone in High-Risk Permanent Atrial Fibrillation

Christian Torp-Pedersen, Christopher B. Granger, Dan Atar, Salim Yusuf, Jonathan L. Halperin, Susan Chrolavicius, Martin Borggrefe, Andrzej Budaj, A. John Camm, Stefan H Hohnloser, Josef Kautzner, A Marco Alings, Campbell D Joyner, Carlos A Morillo, Paul Dorian, Fernando Lanas, Patrick J Commerford, John Amerena, Supachai Tanomsup, Lauri Toivonen, Hermosillo AG, Ernesto Paolasso, Panos N Vardas, Jun-Ren Zhu, Hein Heidbuchel
2011-08-01

Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study

Ype S Tuininga, Hessel F Groenveld, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, Marcelle D Smit, Hans L Hillege, Jan G. P. Tijssen, A Marco Alings, Maarten P van den Berg, RACE II Investigators
2011-10-01

The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study

Ype S Tuininga, Isabelle C Van Gelder, Harry J. G. M. Crijns, Dirk J. Van Veldhuisen, Hans L Hillege, Jan G. P. Tijssen, Hessel F Groenveld, A Marco Alings, Maarten P van den Berg, RACE II Investigators, Adelita Vijaynti Ranchor
2011-05-16

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

John W. Eikelboom, Lars Wallentin, Hans-Christoph Diener, Salim Yusuf, Jonas Oldgren, Stefan H Hohnloser, Muredach P Reilly, A Marco Alings, Jeanne Varrone, Maria Grazia Franzosi, Sean Yang, Mike Ezekowitz, Scott Kaatz
2011-11-01

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial

Lars Wallentin, John W. Eikelboom, Hans-Christoph Diener, Salim Yusuf, Jonas Oldgren, Michael D. Ezekowitz, Muredach P Reilly, A Marco Alings, Harald Darius, Sean Yang, Gabriel Kamenský
2011-08-06

Gender disparities in anxiety and quality of life in patients with an implantable cardioverter-defibrillator.

Luc Jordaens, Susanne S. Pedersen, Dominic A Theuns, A Marco Alings, Pepijn H van der Voort, Krista C van den Broek, Mirela Habibović
2011-08-06

Effect of cardiac resynchronization therapy-defibrillator implantation on health status in patients with mild versus moderate symptoms of heart failure

Luc Jordaens, Susanne S. Pedersen, Dominic A Theuns, A Marco Alings, Pepijn H van der Voort, Krista C van den Broek, Henneke Versteeg

Human - wd:Q114402800

Welcome to Inventaire

de bibliotheek van je vrienden en communities

meer leren